Tegoprubart

特古扑拜单抗

Report date: 2026/03/11 17:21:04

Base Information

Drug NameTegoprubart
Drug Alias NameAnti-CD40L (ALS Therapy Development Institute)Anti-CD40 ligand monoclonal antibody （ALS Therapy Development Institute/Eledon Pharmaceuticals）AT-1501
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-CD40 ligand
TargetsCD40 ligand
Therapy Area/IndicationsRejection of renal transplantationDiabetes Mellitus, Type 1Glomerulonephritis, IGA +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAls Therapy Development Institute
China Registration ClassN/A

Develop Information

Active CompaniesAnelixis Therapeutics LlcEgenesis IncThe University Of Chicago +[5] 
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantationDiabetes Mellitus, Type 1Glomerulonephritis, IGA +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A